Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Trading 06-16 14:53:19 EDT

8.43

+0.03

+0.30%

High8.49	Low8.09	Vol640.94K
Open8.39	D1 Closing8.40	Amplitude4.82%
Mkt Cap872.14M	Tradable Cap595.87M	Total Shares103.52M
T/O5.33M	T/O Rate0.91%	Tradable Shares70.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":8.425,"timestamp":1781635999064,"preClose":8.4,"halted":0,"volume":640937,"delay":0,"changeRate":0.0029761904761905185,"floatShares":70726400,"shares":103517562,"eps":-1.402607,"marketStatus":"Trading","change":0.025,"latestTime":"06-16 14:53:19 EDT","open":8.39,"high":8.49,"low":8.085,"amount":5329381.540945,"amplitude":0.048214,"askPrice":8.43,"askSize":174,"bidPrice":8.42,"bidSize":301,"shortable":3,"etf":0,"ttmEps":-1.402607,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781640000000},"marketStatusCode":2,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":8.4,"preHourTrading":{"tag":"盘前","latestPrice":8.4,"preClose":8.4,"latestTime":"09:28 EDT","volume":27348,"amount":230677.31702400002,"timestamp":1781616480087,"change":0,"changeRate":0,"amplitude":0.071429},"postHourTrading":{"tag":"盘后","latestPrice":8.38,"preClose":8.4,"latestTime":"19:41 EDT","volume":29111,"amount":245084.38,"timestamp":1781566870520,"change":-0.02,"changeRate":-0.002381,"amplitude":0.019048},"volumeRatio":0.438686,"impliedVol":1.2103,"impliedVolPercentile":0.7689},"requestUrl":"/m/hq/s/ORIC/tweets","defaultTab":"tweets","newsList":[{"id":"2642262069","title":"Oric Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2642262069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642262069?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:55","pubTimestamp":1781261730,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K01A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286604","title":"Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286604?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:50","pubTimestamp":1781175045,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE). Om...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omnicell-omcl-oric-pharmaceuticals-oric-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omnicell-omcl-oric-pharmaceuticals-oric-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMCL","BK4139","LU0058720904.USD","LU0868494617.USD","LU1066053197.SGD","BK4588","BK4581","BK4592","PFE","SG9999003800.SGD","LU0225771236.USD","LU0985481810.HKD","LU1883839398.USD","SG9999001176.SGD","BK4167","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU0306807586.USD","LU2596442595.SGD","BK4568","LU0456855351.SGD","BK4533","LU1057294990.SGD","LU0234572021.USD","SG9999002224.SGD","LU1066051498.USD","SG9999013999.USD","BK4599","LU0225284248.USD","LU0321505868.SGD","LU0306806265.USD","BK4550","SG9999002232.USD","LU0321505439.SGD","LU0170899867.USD","BK4007","SG9999001176.USD","IE00BLSP4239.USD","IE00B3T34201.USD","LU1023059063.AUD","IE0002270589.USD","LU1894683348.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","BK4082","LU0289739699.SGD","IE000M9KFDE8.USD","BK4585","BK4534","SG9999011175.SGD","SGXZ57979304.SGD","ORIC","LU0122379950.USD","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641852234","title":"Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2641852234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641852234?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:36","pubTimestamp":1780914964,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiter...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-oric-as-share-price-pullback-creates-opportunity-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-oric-as-share-price-pullback-creates-opportunity-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485979","title":"Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485979","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641485979?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:33","pubTimestamp":1780914780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 06:33 ET (10:33 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140834","title":"Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140834?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:30","pubTimestamp":1780691400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUA57CMZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140315","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140315","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140315?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:30","pubTimestamp":1780691400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June  05, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307620/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904179","title":"Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640904179?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:40","pubTimestamp":1780490412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ardent Health Partners, Inc. (ARDT), Tactile Systems...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ardent-health-partners-inc-ardt-tactile-systems-technology-tcmd-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ardent-health-partners-inc-ardt-tactile-systems-technology-tcmd-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4185","BK4082","BK4585","XLV","BK4137","HCSG","LU0029874061.USD","ORIC","XBI","LU0128526141.USD","LABU","BK4581","TCMD","ARDT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638636780","title":"ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638636780","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638636780?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:05","pubTimestamp":1779912300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May  27, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3302364/0/en/ORIC-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633942529","title":"Oric Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2633942529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633942529?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:04","pubTimestamp":1777997040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 12:04 ET (16:04 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633485819","title":"ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633485819","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633485819?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:15","pubTimestamp":1777983322,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Boris Pe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-backed-by-advancing-oncology-pipeline-phase-3-prostate-cancer-trial-and-2026-nsclc-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-backed-by-advancing-oncology-pipeline-phase-3-prostate-cancer-trial-and-2026-nsclc-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633591790","title":"Piper Sandler Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633591790","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633591790?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:38","pubTimestamp":1777981083,"startTime":"0","endTime":"0","summary":"In a report released today, Kelsey Goodwin from Piper Sandler maintained a Buy rating on Oric Pharmaceuticals, with a price target of $22.00. Goodw...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633991212","title":"Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633991212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633991212?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:18","pubTimestamp":1777979912,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Bradley Canino reiterated a Buy rating on Oric Pharmaceuticals yesterday and set a price target of $18.00. The company’s shares ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-oric-pharmaceuticals-oric-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-oric-pharmaceuticals-oric-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633124969","title":"Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2633124969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633124969?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:18","pubTimestamp":1777979888,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo reiterated a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Archila ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0708994859.HKD","LU0149725797.USD","LU0868494708.USD","LU2361044949.HKD","LU1894683348.USD","LU0029864427.USD","IE00B19Z3B42.SGD","BK4588","LU0980610538.SGD","LU1035773651.USD","LU1267930490.SGD","LU1201861249.SGD","LU0072461881.USD","LU0208291251.USD","LU0162691827.USD","LU0289960550.SGD","LU2361044865.SGD","LU0314106906.USD","LU1280957306.USD","LU0128525689.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU1814569148.SGD","LU1791807156.HKD","BK4207","LU1894683264.USD","LU0130102774.USD","LU0128525929.USD","LU0130517989.USD","LU2361045086.USD","BK4139","LU0310800379.SGD","LU0868494617.USD","IE0002270589.USD","LU0211327993.USD","LU0256863811.USD","LU1363072403.SGD","LU0211328371.USD","ORIC","LU1069347547.HKD","LU0251131958.USD","BK4559","LU0971096721.USD","LU0175139822.USD","BK4585","LU0942090050.USD","LU0310800965.SGD","LU0683600562.USD","LU1267930573.SGD","LU0052756011.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633775919","title":"Oric Pharmaceuticals price target lowered to $16 from $17 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2633775919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633775919?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:39","pubTimestamp":1777977589,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy rating on the shares. Published first on TheFly...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-16-from-17-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-16-from-17-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633966410","title":"Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633966410","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633966410?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926658,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryOric Pharmaceuticals Inc ORIC.OQ reported a quarterly adjusted loss of 34 cents per share for the quarter ende","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H291:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633661479","title":"ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633661479","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633661479?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:29","pubTimestamp":1777926592,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/ORIC","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965966","title":"Oric initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965966?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:24","pubTimestamp":1777926256,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals selected 400 mg once-daily rinzimetostat with darolutamide as recommended Phase 3 dose for Himalayas-1, global registrational trial in post-abiraterone metastatic castration-resistant prostate cancer expected to start in 1H 2026.Early results were already presented, supporting a differentiated safety profile and signs of disease control versus standard therapies, positioning program for late-stage development.Another early dataset in patients previously treated with androgen receptor inhibitors was also presented, showing durability that could extend benefit from hormonal therapy in a setting where responses are typically short-lived.Program update is expected in 2H 2026, with cash and investments of USD 419.7 million projected to fund operations into 2H 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL7FqYkq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633196548","title":"Oric Q1 FY26 net loss widens to $35.77 million; R&D expenses rise to $31.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633196548","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633196548?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:13","pubTimestamp":1777925597,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals posted a Q1 net loss of $35.77 million, widening from $30.02 million a year earlier, while loss per share narrowed to $0.34 from $0.42.Operating loss widened to $39.62 million as R&D expenses climbed to $31.4 million from $24.6 million; G&A held roughly flat at $8.2 million.Cash, cash equivalents and investments totaled $419.7 million, including $59.9 million of net proceeds raised under its ATM program, with runway expected into 2H 2028.Selected rinzimetostat 400 mg once daily as recommended Phase 3 dose with darolutamide, targeting initiation of Himalayas-1 Phase 3 registrational trial in post-abiraterone mCRPC in 1H 2026.Completed enrollment in enozertinib Phase 1b monotherapy in first-line EGFR exon 20 insertion NSCLC, with several enozertinib clinical updates expected in 2H 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8srFy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014021.USD","LU2210150020.SGD","BK4112","LU0314104364.USD","BK4588","SG9999014039.USD","SG9999014013.SGD","BK4139","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","NDAQ","IE00BKPKM429.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633996582","title":"BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633996582","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633996582?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925148,"startTime":"0","endTime":"0","summary":"BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million\n\n\nMay 04 (Reuters) - ORIC Pharmaceuticals Q1 income from operations USD -39.619 million.\n\nQ1 net income USD -35.767 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXCABFA8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633896321","title":"Oric Pharmaceuticals Q1 Operating Expenses USD 39.619 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633896321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633896321?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925103,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXCABFA8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":0.1155},{"period":"1month","weight":0.0307},{"period":"3month","weight":-0.3041},{"period":"6month","weight":0.0219},{"period":"1year","weight":-0.1277},{"period":"ytd","weight":0.0269}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.173514},{"month":5,"riseRate":0.571429,"avgChangeRate":0.047029},{"month":6,"riseRate":0.571429,"avgChangeRate":0.120049},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.000511},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}